U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
JERSEY CITY, N.J., March 29, 2017 -- SCYNEXIS, Inc. (NASDAQ:SCYX), a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs, today announced that the Company will present at the 16th Annual Needham Healthcare Conference at The Westin New York Grand Central on Wednesday, April 5, 2017 at 1:40 p.m. ET.
A live webcast will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
About SCYNEXIS
SCYNEXIS is a drug development company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
CONTACT: Media Relations Cammy Duong MacDougall Biomedical Communications Tel: 781-591-3443 [email protected] Investor Relations Susan Kim Argot Partners Tel: 212-203-4433 [email protected]
